New personalized cancer vaccine shows promise in early trial

NCT ID NCT06631079

Ongoing Disease control Sponsor: NEC Bio B.V Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the combination can help control tumor growth. Participants must already be on immunotherapy and have stable or responding disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Personalized oral DNA cancer vaccine (NECVAX-NEO1) plus standard immunotherapy (PD-1/PD-L1 inhibitors)
What this could lead to: If successful, this could offer a new way to boost the immune system's ability to fight solid tumors, potentially improving tumor control when combined with standard immunotherapy.
What could go wrong: This is an early-phase trial with only 20 participants, so results may not apply to all patients. The vaccine is personalized, which is complex and may not work for everyone. Side effects from the combination therapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

CHUS Santiago de Compostela

Santiago de Compostela, Spain
Charité

Berlin, Germany
Comprehensive Cancer Center

Munich, Germany
Fundacion Jimenez Diaz

Madrid, Spain
Institut Catala d'Oncologia

Barcelona, Spain
NCT

Heidelberg, Germany
National Cancer Center

Vilnius, Lithuania
Vall d'Hebron

Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.